In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Paradoxical low-flow/low-gradient severe aortic stenosis: prevalence and distinctive characteristics in comparison to high-gradient aortic stenosis

Session Poster session 3

Speaker Christopher Strong

Event : EuroEcho 2017

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Aortic Valve Stenosis
  • Session type : Poster Session

Authors : C Strong (Lisbon,PT), MJ Andrade (Lisbon,PT), G Cardoso (Lisbon,PT), M Canada (Lisbon,PT), R Ribeiras (Lisbon,PT), C Reis (Lisbon,PT), E Horta (Lisbon,PT), M Mendes (Lisbon,PT)

Authors:
C Strong1 , MJ Andrade1 , G Cardoso1 , M Canada1 , R Ribeiras1 , C Reis1 , E Horta1 , M Mendes1 , 1Hospital de Santa Cruz, Cardiology - Lisbon - Portugal ,

Citation:
European Heart Journal Supplements ( 2017 ) 18 ( Supplement 3 ), iii194

Background: Paradoxical low-flow/ low-gradient aortic stenosis (PAS) has been described in up to 30% of patients with AS and preserved left ventricular ejection fraction (LVEF), and characterized by a higher prevalence of female sex, small body surface area, older age and systemic hypertension. Moreover, some reports showed this subtype of AS to have an increased risk of mortality compared with other subtypes of AS with preserved LVEF (normal-flow/ low-gradient and high-gradient).

Purpose: To evaluate the prevalence of PAS and to compare clinical and echocardiographic characteristics, differences in therapeutic management and overall survival between patients with this entity and those with classical high-gradient (HG) AS.

Methods: Single center, retrospective study of patients with severe AS evaluated by transthoracic echocardiography between January 2012 and May 2017. All patients with severe PAS (AVA 1 cm2, MG<40 mmHg and SVi<35 ml/m2) were selected. For the control group, the first patient with classical HG AS of each month throughout this 5-year period was selected. Clinical, echocardiographic, types of treatment and outcome data were assessed and compared between groups.

Results: Out of 1250 patients with AS evaluated over this period, only 34 (2,7%) fulfilled the criteria for paradoxical severe AS, with a mean age of 78±6 years and 56% of female patients. The control group included 65 patients with severe classical HG AS, with a mean age of 77±9 years, 51% females. Using a binary logistic regression, the variables that correlated significantly with paradoxical AS were: atrial fibrillation (AF) rhythm (OR 30 with 95% C.I. [6, 161], p<0.01), at least moderate mitral regurgitation (MR) (OR 6 with 95% C.I. 1, 29], p 0.02), and right ventricular (RV) dysfunction (OR 35 with a 95% C.I. [2, 533], p 0.01). No differences were observed between the 2 groups regarding gender, age, hypertension, body surface area, chosen management strategy (medical therapy vs valvular replacement), type of treatment used (TAVI vs conventional surgery) or outcome.

Conclusion: In our population, paradoxical low-flow/low-gradient AS is a rare subtype of AS. In comparison with patients with classical HG AS, patients with PAS are characterized by a higher prevalence of AF, moderate or severe mitral regurgitation and RV dysfunction. We did not find differences regarding the chosen therapeutical management or outcome.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are